ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 92 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

    (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  M1:wNWNmdGxiVnnhZoltcXS7IFHzd4F6 MlfVNlUxKG6PwrC= NWLUU3dOPzJiaB?= NI\hVlVFVVOR MV;jZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6|ZnXjeIVlKHerdHigRmNNPiC|aWLORS=> NV\SbWU6OjZ4NUeyPFg>
KG1a NFjPfWpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4DESVAuOTBizszN MVmyOEBp NILj[IZFVVOR NYfFXlc1UUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYrwbXViOjZ3NUK3NVI>
Kasumi-1 NHzPfGhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVK4N4lOOC1zMDFOwG0> NX\WT4YxOjRiaB?= NW\2fpVPTE2VTx?= NFfRN29KSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYiyOlU2OjdzMh?=
KG1a Ml3RRZBweHSxc3nzJGF{e2G7 MYGwMVExKM7:TR?= MkXFNlQhcA>? MlzMSG1UVw>? Mly0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mlm4NlY2PTJ5MUK=
Kasumi-1 NF;ETlBCeG:ydH;zbZMhSXO|YYm= MmfiNE0yOCEQvF2= MnTtNlQhcA>? MoHWSG1UVw>? MofXbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYr2Oo53OjZ3NUK3NVI>
MC-3  M2jYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu1M|ExNzJyIN88US=> NXvucmxxOjRiaB?= NHnNc29FVVOR M{O1UIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWCyOlQ1PzZzNR?=
HN22  NGnES5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHINk42NzdwNT:yNk42KM7:TR?= MXyyOEBp MYfEUXNQ NUX6eVJQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFKxSWszPjR2N{[xOS=>
MC-3  NY\4VYl[SXCxcITvd4l{KEG|c3H5 M3eyVVUwOTBxMkCg{txO NH62Tm0zPCCq MmCzSG1UVw>? Mnu3bY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= NYHYWlV7OjZ2NEe2NVU>
HN22  MWHBdI9xfG:|aYOgRZN{[Xl? MnPlNk42NzdwNT:yNk42KM7:TR?= MmmyNlQhcA>? NYjyW|g2TE2VTx?= Mk[zbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= NXL1[HBmOjZ2NEe2NVU>
MOLT-4 NFuwUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexNE02ODByIH7N M3jObVczKGh? M37Kd2ROW09? NVjCSZZvUUN3ME2wMlE6QCEQvF2= M4KyfVI3Ozl{M{Oy
RS4;11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrOTngyOC13MECwJI5O NF;2dXE4OiCq MVPEUXNQ MlfHTWM2OD1yLkCwNkDPxE1? MYSyOlM6OjN|Mh?=
JURKAT NHjp[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXexNE02ODByIH7N MYC3NkBp MWHEUXNQ NELPfZVKSzVyPU[2JO69VQ>? NWjlOo9rOjZ|OUKzN|I>
CEM R MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfBNVAuPTByMDDuUS=> NV;Bc4xtPzJiaB?= NFq0eIRFVVOR NF[z[4hKSzVyPUWuOEDPxE1? NFHSUVczPjN7MkOzNi=>
CEM S MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnZSYFqOTBvNUCwNEBvVQ>? M2jINlczKGh? NFHXOWlFVVOR M2XUO2lEPTB;MUKuNUDPxE1? NEPoS|UzPjN7MkOzNi=>
MOLT-4 NFTQZY1CeG:ydH;zbZMhSXO|YYm= NWT0fGZmOTBvMUCwNEBvVQ>? NYDz[FZWOjRiaB?= NUizU|cyTE2VTx?= NY\PXYNu[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE> MlvzNlY{QTJ|M{K=
CEM S MX3BdI9xfG:|aYOgRZN{[Xl? MofaNVAuOTByMDDuUS=> MYmyOEBp MXTEUXNQ Ml7OZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= M1nuVVI3Ozl{M{Oy
JURKAT NXHS[5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHUUY4yODBvMUCwNEBvVQ>? MorhOFghcA>? MXTEUXNQ NYrEZWxDUUN3ME25OVXDuTlwMzDuUS=> MVeyOlE4OjJ4OR?=
LOUCY M1zPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLQToYxOTByLUGwNFAhdk1? MnTIOFghcA>? NXXXVlVTTE2VTx?= NUPEfo4yUUN3ME2zNk45yrFzMD65JI5O M4XiXVI3OTd{Mk[5
WM-115 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXG3b2pTOTBywrDuUS=> MWS3NkBp NH;JcYZmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MnjlNlYyOTZ5N{[=
B16 Mly0R4VtdCCYaXHibYxqfHliQYPzZZk> NHfr[5gyODEEoH7N M3rQelczKGh? NVvPSmlu\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= MV6yOlEyPjd5Nh?=
HL-60  NFy3NXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPmdZo4OiCq NGrnfnBKSzVywrC9JFExNjdibl2= MnjSNlYxPDV4MEm=
MOLM-13  M{nROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr6WmI4OiCq NXXmcZROUUN3MNMgQUAzPy57IH7N NVvx[IExOjZyNEW2NFk>
OCI-AML3 NUXIbnpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSyO|IhcA>? NUOzUoluUUN3MNMgQUAyQTVyIH7N M3vNbVI3ODR3NkC5
BCWM.1 NXz3d4NVSXCxcITvd4l{KEG|c3H5 MkPLNE0yNjZizszN NU\SSXZROjRiaB?= MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkLyNlU5QTN{OUC=
MWCL-1 NYC1bYh4SXCxcITvd4l{KEG|c3H5 M3foS|AuOS54IN88US=> M{TZOlI1KGh? M1HwbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mn\tNlU5QTN{OUC=
MM.1s MVHBdI9xfG:|aYOgRZN{[Xl? M4XU[FAuOS54IN88US=> MWOyOEBp MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1HZc|I2QDl|Mkmw
HCT116 NYHS[HZSTnWwY4Tpc44hSXO|YYm= MnPnN{8yOCEQvF2= NYDZeHZ3OTMEoHlCpC=> M3[0cWROW09? M2HETolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= NEnKZpkzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO M1m0NGZ2dmO2aX;uJGF{e2G7 NVLmVnFPOy9zMDFOwG0> NV\rTYgyOTMEoHlCpC=> NU\QO4RpTE2VTx?= MlqybY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w M3jKOlI2PzF3MEK4
HCT116 M1jSZWZ2dmO2aX;uJGF{e2G7 MmO5NVAh|ryP NYrCVW1JOTMEoHlCpC=> NFTJdodFVVOR Mk\TbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?= M1LjO|I2PzF3MEK4
HCT116 BAX BAK1 DKO M1rL[GZ2dmO2aX;uJGF{e2G7 NGrHR48yOCEQvF2= MXKxNuKhcMLi NY\nNHBNTE2VTx?= MWLpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj MUOyOVcyPTB{OB?=
HCT116 MlT1RZV1d3CqYXf5JGF{e2G7 NYqwVnJEOTBizszN NF;qN5oyOsLiaNMg MmXaSG1UVw>? Ml;TbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW|cH;ud4U> MYOyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO NIT2VHFCfXSxcHjh[5khSXO|YYm= MYqxNEDPxE1? Mn;hNVLDqGkEoB?= NF:0R3lFVVOR NFn1WZRqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? NEj3PG4zPTdzNUCyPC=>
U937 MYTBdI9xfG:|aYOgRZN{[Xl? MXKwMlEzPS1{IN88US=> MXiyOEBp NIHpXnhmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHXUPIwzPTdzNECyOC=>
U937  MXfBdI9xfG:|aYOgRZN{[Xl? MWSwMlUh|ryP MUiyOEBp MV3lcohidmOnczDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMh[XNid3XscEBieyCQb4jhJIxmfmWu Ml\UNlU4OTRyMkS=
HL-60 AAA-Bcl-2 NYHEbGJpSXCxcITvd4l{KEG|c3H5 MkjZNE02KM7:TR?= NFXNNpA1QCCq MkO5TWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{TTN|I2PzFzNE[w
HL-60 EEE-Bcl-2 MlfNRZBweHSxc3nzJGF{e2G7 NVSzPGFDOC13IN88US=> MWG0PEBp NGPadFRKSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXeyOVcyOTR4MB?=
U87 NGj1fpVHfW6ldHnvckBCe3OjeR?= NWrINY9DPTBizszN NEnySJkzPCCq NHrrb3dz\WS3Y3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKE2PUD2yMEBOVVBvMUSgZY5lKEKlbD2y M2e4bFI2PjZ5Nk[z
K562 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV72TW9wOS1zMDFOwG0> M2f0OVQ5KGh? Mo\6SG1UVw>? NYn2UoE4UUN3ME2yOk44KM7:TR?= NUfvdJM5OjV3OU[1OlE>
K562/Mcl -1-IRESBim MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vpfWlEPTB;OT6zJO69VQ>? MlHiNlU2OzV7MEC=
K562/Bcl- 2-IRESBim Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzRXlJSUUN3ME2wMlM2KM7:TR?= NInm[4YzPTV|NUmwNC=>
Jurkat M1G1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PsWWlEPTB;MD62OkDPxE1? NHq3flEzPTV|NUmwNC=>
JurkatΔBak Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P3d2lEPTB-NUCg{txO NWewcXVxOjV3M{W5NFA>
HL60/VCR M1ewSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRjFyMDFOwG0> NE\xRWozPTV|NUmwNC=>
Kasumi-1 NY\Jb|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmniTWM2OD1yLkCxJO69VQ>? NWe3fo9YOjV3M{W5NFA>
Kasumi-1/ABT NWX1PVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKyZXZVUUN3ME2wMlUyKM7:TR?= NW\zVZNXOjV3M{W5NFA>
THP-1 NEDKSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfRTWM2OD1zLkK3JO69VQ>? MljlNlU2OzV7MEC=
U937 M1vWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG1UYJKSzVyPUWuNlkh|ryP M2LyclI2PTN3OUCw
C1498 M3jkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLkTWM2OD14LkGzJO69VQ>? NYDRW5hrOjV3M{W5NFA>
RPMI 8226 NH2y[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO3TWM2OD1yLkK1JO69VQ>? MWqyOVU{PTlyMB?=
MM.1S NH\lTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXTTWM2OD1yLkSwJO69VQ>? NGHBUFMzPTV|NUmwNC=>
NCI-H929 NG\ySo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HEZmlEPTB;MUWuNlEh|ryP NG\Ie|UzPTV|NUmwNC=>
U266 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL1b4Q5UUN3ME2wMlY5KM7:TR?= NFf5ZXAzPTV|NUmwNC=>
MCF-7 Ml63R4VtdCCYaXHibYxqfHliQYPzZZk> M2m5Z|Uh|ryP M4nVVVQ5KGh? MVfEUXNQ MmXw[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? NX70ZXBXOjV2MEmxNlQ>
MCF-7 MUnBdI9xfG:|aYOgRZN{[Xl? M1i2RVUh|ryP NVzCNnJ2PC9{ND:0PEBp M{LzOGROW09? NXrmbGxScW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA> M2TqTFI2PDB7MUK0
MCF-7 MY\GeY5kfGmxbjDBd5NigQ>? NEDlO|Y2KM7:TR?= MnrqNlQhcA>? MlnUSG1UVw>? NXG4W4hq\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MmHNNlU1ODlzMkS=
MDA-MB 231  MnvxSpVv[3Srb36gRZN{[Xl? NYG3ZXUxPSEQvF2= Ml;2NlQhcA>? Mn\wSG1UVw>? NX7DZ5Jj\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi M4n5fVI2PDB7MUK0
ZR-75-1  NEWzdHRHfW6ldHnvckBCe3OjeR?= MVG1JO69VQ>? Ml7mNlQhcA>? NGi5U3NFVVOR M{nmOYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? Ml\TNlU1ODlzMkS=
A549 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NILhXIUxNTJyIN88US=> MVi3NkBp MoHZSG1UVw>? MXHk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MWSyOVM5QDd4Mh?=
H1299 NVrnS2R2S2WubDDWbYFjcWyrdImgRZN{[Xl? MkHJNE0zOCEQvF2= NFHVZYc4OiCq NGnn[YRFVVOR NX\ES3dk\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NIfnfnAzPTN6OEe2Ni=>
HO-8910 NFTzdoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnXaNE0zOCEQvF2= MlW0O|IhcA>? MortSG1UVw>? NXzwR5V5\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NFzoUFQzPTN6OEe2Ni=>
HT-29 NWrjPI9bS2WubDDWbYFjcWyrdImgRZN{[Xl? M3\Je|AuOjBizszN M2fpb|czKGh? MVrEUXNQ NFvmNI1l\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw M4jhfVI2Ozh6N{[y
HCT-116 NHLEeoZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWqwMVIxKM7:TR?= NYTLfnd2PzJiaB?= NYTCVHkxTE2VTx?= MoLj[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? M4T2UlI2Ozh6N{[y
A549 NVfOW|VVSXCxcITvd4l{KEG|c3H5 M1rqT|IxKM7:TR?= MoPzOFghcA>? NG\MNFJFVVOR MorNbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= M2j2O|I2Ozh6N{[y
H1299 MoHJRZBweHSxc3nzJGF{e2G7 NU\hTFdyOjBizszN NVX1Vlk1PDhiaB?= NYLacJM6TE2VTx?= MXnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NXzSXFlwOjV|OEi3OlI>
Sc-1 Mk\rR4VtdCCYaXHibYxqfHliQYPzZZk> M3PQRVAvODByMT2xJO69VQ>? MWi5OkBp MXnk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYLQXppoOjV|N{O1NFg>
OcI-LY18 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlvQNE4xODBzLUGg{txO MUS5OkBp MYPk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFrEW24zPTN5M{WwPC=>
RL  NUXZN5dZS2WubDDWbYFjcWyrdImgRZN{[Xl? NUSwNIRDOC5yMECxMVEh|ryP NXXBUJpzQTZiaB?= NYXydGxk\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoH3NlU{PzN3MEi=
RKO NE\tVGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXSwMVExKM7:TR?= NHKydlQzPOLCiXlCpC=> MWDEUXNQ Mlu4TWM2OD8kgJmyOgKBkcL3TR?= MVyyOVMxPDN6Mx?=
Caco-2 M4D5SmNmdGxiVnnhZoltcXS7IFHzd4F6 MUiwMVExKM7:TR?= NIHzZpYzPOLCiXlCpC=> NY[5cHJNTE2VTx?= NGezXXpKSzVyPUG5MlfjiIoEtV2= M{XzfFI2OzB2M{iz
DLD1 NVW0fGxnS2WubDDWbYFjcWyrdImgRZN{[Xl? NVP2WlRoOC1zMDFOwG0> M{D6Z|I16oDLaNMg M3TvdWROW09? MVfJR|UxRTF6Lke45qCKyrWP M{PLPVI2OzB2M{iz
LS411N NIP4UndE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmPuNE0yOCEQvF2= NUPSfZhHOjUkgJnoxsA> NIj3N4hFVVOR NIHnO2lKSzVyPUGxMlQ46oDLwsXN NWfUPGp5OjV|MESzPFM>
SW620 M{jNZWNmdGxiVnnhZoltcXS7IFHzd4F6 M2PacFAuOTBizszN M{DqXlI16oDLaNMg MonXSG1UVw>? Mk\KTWM2OD1zMj6yOQKBkcL3TR?= NFPoTFAzPTNyNEO4Ny=>
HCT116 NXXTUXk5S2WubDDWbYFjcWyrdImgRZN{[Xl? MYCwMVExKM7:TR?= NHHKTmwzPOLCiXlCpC=> NXnSeGoyTE2VTx?= NHvrdGtKSzVyPUKwMlQ66oDLwsXN MU[yOVMxPDN6Mx?=
HaCaT MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NY\abYRPOC5zL{GvNVAh|ryP MVqyOEBp NX\VR4I3TE2VTx?= M1XteoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2nJR|I2OjFyN{m1
A5-RT3 M1\pbGNmdGxiVnnhZoltcXS7IFHzd4F6 NYXqUWhuOC5zL{GvNVAh|ryP M1HQXFI1KGh? MWjEUXNQ MXXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo\jNlUzOTB5OUW=
HaCaT NYC1XnJiTnWwY4Tpc44hSXO|YYm= NXPJNm9UOTEkgJpOwG0> MX6yOE81QCCq NFHx[lJFVVOR NF7rNXZqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= M1rEPVI2OjFyN{m1
A5-RT3 MWDGeY5kfGmxbjDBd5NigQ>? M2XyTVEx6oDLzszN MojaNlQwPDhiaB?= NFTiPIdFVVOR NIPuSIxqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= NYLS[o8xOjV{MUC3PVU>
A5-RT3 NHn0fFBHfW6ldHnvckBCe3OjeR?= NED2TWw2KM7:TR?= NGLRUG03KGh? M{W0TWROW09? NWe1e3pKcW6mdXPld{B1cGVicnXs[YF{\SCxZjDtbZRw[2ixbnTybYFtKHC{b4TlbY5{KGGwZDDy[YR2[2W|IHPsc45w\2WwaXOgd5Vzfmm4YXygbY4h[SClYYPwZZNmNWmwZHXw[Y5l\W62IH3hco5meg>? MXeyOVIyODd7NR?=
U266 MoXwSpVv[3Srb36gRZN{[Xl? NGi1TWY2ODBxN{WwJI5O MXOyOE81QCCq NH3XeVZFVVOR MlLC[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt MXGyOVIxQDh6OB?=
RPMI8226 MVjGeY5kfGmxbjDBd5NigQ>? NVPOSYhsPTByL{e1NEBvVQ>? MUeyOE81QCCq M{TWOWROW09? M125PYRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> M4rlUVI2OjB6OEi4
MM.1S M{G1ZmZ2dmO2aX;uJGF{e2G7 M2n5SVUxOC95NUCgcm0> NWnyfphxOjRxNEigbC=> MlzFSG1UVw>? Ml23[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M{P0NVI2OjB6OEi4
Clone A MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnhNHIxNjMkgKO2NEDPxE1? NWO1e21QPzJiaB?= NX7MbXVzTE2VTx?= NVn5dI1TUUN3ME23MlUh|ryP MY[yOVIxQDh6Mh?=
CX-1 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCwMlLjiJN4MDFOwG0> M3LNPFczKGh? NVi2XnFrTE2VTx?= M37BSGlEPTB;MT64JO69VQ>? NH\zUYIzPTJyOEi4Ni=>
LS174T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLMZ4l7OC5{4pETOlAh|ryP M1TEeFczKGh? NE[3O|VFVVOR MVPJR|UxRTF6LkOg{txO NXj1[mppOjV{MEi4PFI>
HT29 NWTJNmUxSXCxcITvd4l{KEG|c3H5 Ml;DNU82NzFyIN88US=> MXy0PEBp M3T4[YNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MY[yOVE6OjF6OB?=
SW480 NWjPTpNiSXCxcITvd4l{KEG|c3H5 NHLaTWsyNzVxMUCg{txO MWO0PEBp Ml7NZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NW\jeo5POjVzOUKxPFg>
Colo205 MoL4RZBweHSxc3nzJGF{e2G7 MUmxM|UwOTBizszN M{HoXlQ5KGh? MVvjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4HFbVI2OTl{MUi4
Caco2 NImwRYlCeG:ydH;zbZMhSXO|YYm= NXTv[GdWOS93L{GwJO69VQ>? NXXqTm9NPDhiaB?= M4TlbINifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlLMNlUyQTJzOEi=
PCI-13 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DZVFczKGh? MlHiSG1UVw>? M1LYW2dKPTB;MUWgxtEhOS56IN88US=> MWOyOVE{QTN6Nx?=
PCI-15B MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWW3NkBp M3niXmROW09? NV\qO4dVT0l3ME2xNUDDuSB2LkWg{txO NEPRc|QzPTF|OUO4Oy=>
UM-SCC22B M3jnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NkBp Mmr1SG1UVw>? NELh[VJIUTVyPUG5JOKyKDJwOTFOwG0> M4HUN|I2OTN7M{i3
UM-SCC47 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3NkBp M4n5RmROW09? NXz2[XRwT0l3ME2xPUDDuSBzMj6zJO69VQ>? NYjye25LOjVzM{mzPFc>
93-VU-147T M{T5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTtUVRDPzJiaB?= MYrEUXNQ NIXEb2NIUTVyPUSuN{DDuSB|LkWg{txO MXGyOVE{QTN6Nx?=
UD-SCC2 NG\0ZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmydJM4OiCq NGnSWpJFVVOR M2HHdWdKPTB;MkigxtEhOi57IN88US=> M1\IUFI2OTN7M{i3
UPCI:SCC90 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjIWZNCPzJiaB?= MYPEUXNQ NYm4PXZwT0l3ME22MlYhyrFiMT61JO69VQ>? NFLrcpIzPTF|OUO4Oy=>
RPMI-8226  MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmjRNVI2NzJ3MD:1NFAhdk1? Ml\hOFhpyqB? MofYSG1UVw>? MXjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmjzNlUxODh{MEK=
OPM-2  Ml\hR4VtdCCYaXHibYxqfHliQYPzZZk> MoftNVI2NzJ3MD:1NFAhdk1? M3nsVlQ5cMLi NWDJNY1JTE2VTx?= M4XwfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1\lSlI2ODB6MkCy
RPMI-8226  Mnr5RZBweHSxc3nzJGF{e2G7 NFnaNooyOjVxMkWwM|UxOCCwTR?= NEm0WG01QGkEoB?= MlnsSG1UVw>? NIDhOFRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1P5WFI2ODB6MkCy
OPM-2  NESzWJlCeG:ydH;zbZMhSXO|YYm= MYixNlUwOjVyL{WwNEBvVQ>? NIHGTGQ1QGkEoB?= NVLNe4RxTE2VTx?= NF3kW|BqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmL1NlUxODh{MEK=
COG-LL-319 MlrPSpVv[3Srb36gRZN{[Xl? MXyxNFAhdk1? NYLrTYhOOS9|L{[gbC=> Ml\xSG1UVw>? MVLpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm MofvNlQ6PTF2N{K=
RS4;11 MWLGeY5kfGmxbjDBd5NigQ>? M2G1WFExOCCwTR?= M2CwVlEwOy94IHi= NGLhRYJFVVOR MXvpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm M2DpU|I1QTVzNEey

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID